Medical Archives | Report Store | Pharma intelligence

Eight Talking Points from ESMO

At the 2019 congress in Barcelona from 27 September to 1 October, the European Society for Medical Oncology (ESMO) proved once again it is a match for ASCO. Scrip shares the main points of the event including Seattle Genetics victory for mid-caps.

September 2, 2019

Find out more

Culture Change At GSK: ‘We’re Doing What We Said We’d Do’

$131.00

Hal Barron, Chief scientific officer at GSK recently spoke about winning the hearts and minds of 10,000 R&D employees and adopting practices from acquired company, Tesaro. Scrip covers the talk topics including how doubters are coming around amid recent successful approvals

September 2, 2019

Find out more

ESMO Preview: Five Key Oncology Battlegrounds To Watch

$200.00

With Europe’s biggest cancer congress ESMO attracting large and small companies to present the latest data readouts across a broad range of tumor types, Scrip looked at the key players and the five key battlegrounds at stake.

August 3, 2019

Find out more

Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up

$200.00

Shortly after US FDA approval of its blood-disorder drug Cablivi, Sanofi announced “a rigorous pipeline prioritization review.” It’s fast-tracking 17 programs and discontinuing 13 development and 25 research projects. What’s left? Will Sanofi divest its animal health and/or consumer healthcare units? Find out what experts are saying.

February 7, 2019

Find out more

The Case For CAR-T Grows As Responses Hold Up Longer Term

$200.00

Scrip speaks with Pascal Touchon, Senior Vice President and Global Head, Cell & Gene Therapy at Novartis AG about the company’s encouraging successes with CAR-T therapies, as evidenced by 18-month data released during the December 2018 meeting of the American Society of Hematology.

December 20, 2018

Find out more

GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals

$200.00

GlaxoSmithKline PLC and Pfizer Inc. agreed to an all-equity deal that sees the two pharma giants teaming up for a consumer healthcare product joint venture. Explore the ins and outs of the deal, and how it positions both GSK and Pfizer, as each are looking to raise investor confidence.

December 19, 2018

Find out more

FDA Asks Whether Supplement Industry Has Outgrown Regulatory Framework

$131.00

A working group appointed by US FDA Commissioner Scott Gottlieb convened to study the FDA’s capacity to handle the supplement sector and the potential need for Congress to legislate improvements to the agency’s oversight powers in the supplement space.

December 12, 2018

Find out more

The Oncology Burden Of Proof: Learning From The PD-1 Market

$200.00

In Vivo interviews Eva Marchese, VP at consulting group Charles River Associates, for insights into the challenges facing the PD-1/LD1 European market’s reimbursement and access schemes for IO products. Gain insights into the sustainability obstacles for immuno-oncology products in this vital interview.

November 7, 2018

Find out more

The Emergence Of IO

$131.00

Immuno-oncology: spurred by the approval of first-generation checkpoint inhibitors in 2014, this important market has continued to grow exponentially, as deals are made not only around checkpoint inhibitors themselves, but also for related molecules and technologies to be used in synergy with them. Examine the origins of this important and growing area in this essential In Vivo report.

October 24, 2018

Find out more

Immuno-Oncology: Unicorns, China And The Perfect Storm

$200.00

Immuo-oncology is proving to be that rare animal for investors in pharma, where return on invested capital doesn’t seem necessarily tied to risk, with mature assets returning liquidity similar to those of early assets. Examine transaction trends, investor activity, and the exit landscape for this important area.

October 24, 2018

Find out more

Cancer’s New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

$200.00

As the number of cancer survivors increases, they are reshaping cancer research and clinical practice. Find out how–and discover the impact it will have on the allocation of research dollars. Learn how the looming physician shortage has implications for the emergence and increasing use of complex immunotherapy drugs.

August 6, 2018

Find out more

Immuno-Oncology: What To Watch At ASCO 2018

$200.00

Immunotherapy dominated the American Society of Clinical Oncology 2018 annual meeting. PD-1/L1 inhibitors were among those taking center stage–find out which ones hold the most promise for NSCLC. Gain insights into why Jounce’s ICOS antibody JTX-2011 proved to be such a disappointment–and why this affects Celgene investors.

May 17, 2018

Find out more